GlassScriptPhysician profile
Zeeshan Ali
NPI 1962780536
$1,225.28
in general payments reported to CMS, 2019-2025
21 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.99 · 2020: $99.95 · 2022: $224 · 2023: $414 · 2024: $108 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.27 |
| Education | $357.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $494.88 | 2020-2025 | |
| Glaxosmithkline, LLC. | $113.40 | 2025 | Ojjaara |
| Kite Pharma, INC. | $94.16 | 2025 | |
| Genentech USA, INC. | $71.99 | 2019 | |
| Taiho Oncology, INC. | $52.39 | 2022-2023 | |
| Celgene Corporation | $48.67 | 2023 | Pomalyst, Opdualag |
| Beigene USA, INC. | $41.21 | 2023 | Brukinsa |
| Adaptive Biotechnologies Corporation | $34.02 | 2022-2023 | Clonoseq |
| Novartis Pharmaceuticals Corporation | $32.80 | 2023 | |
| Merck Sharp & Dohme LLC | $31.18 | 2022-2023 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $26.59 | 2022-2023 | |
| Acrotech Biopharma INC. | $22.75 | 2023 | Beleodaq |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Eisai INC. | $20.29 | 2022 | |
| Genzyme Corporation | $20.05 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $19.86 | 2022 | |
| Amgen INC. | $18.69 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.24 | 2023 | Calquence |
| Seagen INC. | $17.38 | 2023 | Padcev |
| Pfizer INC. | $13.16 | 2023 | |
| Rigel Pharmaceuticals, INC. | $12.57 | 2024 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeeshan Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.